Offers a potential new standard of care through an all-oral, biomarker-driven frontline strategy for MET-overexpressing, EGFR ...
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of improvement in affect and behavior, ...
UPPSALA, SE / ACCESS Newswire / October 26, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime invites investors, analysts, and ...
LUND, SE / ACCESS Newswire / October 26, 2026 / Cantargia AB (publ)(STO:CANTA), a clinical-stage biotechnology company ...
The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining ...
BG-C477 is the first ADC to emerge from BeOne’s internal drug discovery organization. With a proprietary CEA (or CEACAM5) ...
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after ...
At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase ...
Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five ...
In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary ...
Presented first-in-class clinical proof-of-concept data in KRAS G12D mutant CRC with combination of QTX3034 and anti-EGFR ± ...
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results